Therapeutic blockade of IL-1 alleviates fatigue in patients with rheumatoid arthritis, diabetes type 2, primary Sjögren’s syndrome and cancer-related fatigue.29, , –32 HMGB1 activates macrophages and microglia to produce and release IL-1β. Here, HMGB1 is linked to type 2 diabetes mellitus.